Evaluation of serum TWEAK concentration in patients with acute pancreatitis

References

• Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008;7:411–25.
   PubMed Web of Science ®Google Scholar
• Zheng TS, Burkly LC. No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies. J Leukoc Biol 2008;84:338–47.
   PubMed Web of Science ®Google Scholar
• Dogra C, Changotra H, Mohan S, Kumar A. Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J Biol Chem 2006;281:10327–36.
   PubMed Web of Science ®Google Scholar
• Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE, Kumar A. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 2007;21:1857–69.
   PubMed Web of Science ®Google Scholar
• Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, McKinlay M, Benetatos CA, Condon SM, Chunduru SK, Yeoh G, Brink R, Vaux DL, Silke J. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008;182:171–84.
   PubMed Web of Science ®Google Scholar
• Puolakkainen P, Valtonen V, Paananen A, Schroder T. C-reactive protein (CRP) and serum phospholipase A2 in the assessment of the severity of acute pancreatitis. Gut 1987;28:764–71.
   PubMed Web of Science ®Google Scholar
• Dominguez-Munoz JE, Carballo F, Garcia MJ, de Diego JM, Rabago L, Simon MA, de la Morena J. Clinical usefulness of polymorphonuclear elastase in predicting the severity of acute pancreatitis: results of a multicentre study. Br J Surg 1991;78:1230–4.
   PubMed Web of Science ®Google Scholar
• Gudgeon AM, Heath DI, Hurley P, Jehanli A, Patel G, Wilson C, Shenkin A, Austen BM, İmrie JW, Hermon-Taylor J. Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis. Lancet 1990; 335:4–8.
   PubMed Web of Science ®Google Scholar
• Granger J, Remick D. Acute pancreatitis: models, markers, and mediators. Shock 2005;24 1:45–51.
   Google Scholar
• Hession C, Garcia I, Browning JL. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997;272:32401–10.
   Google Scholar
• Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashekenazi A. Identification of a ligand for the deathdomain containing receptor Apo3. Curr Biol 1998;8:525–8.
   PubMed Web of Science ®Google Scholar
• Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lössner U, Blüher M, Stumvoll M, Fasshauer M. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008;199:440–4.
   PubMed Web of Science ®Google Scholar
• Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány P, Heimbürger O, Marrón B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:110–8.
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, Orbe J, Páramo JA, Michel JB, Ortiz A, Meilhac O, Egido J. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:916–22.
   PubMed Web of Science ®Google Scholar
• Kamata K, Kamijo S, Nakajima A, Koyanagi A, Kurosawa H, Yagita H, Okumura K. Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol 2006;177:6433–9.
   PubMed Web of Science ®Google Scholar
• Yepes M, Winkles JA. Inhibition of TWEAK activity as a new treatment for inflammatory and degenerative diseases. Drug News Perspect 2006;19:589–95.
   PubMedGoogle Scholar
• Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003; 14:241–9.
   PubMed Web of Science ®Google Scholar
• Desplat-Jego S, Varriale S, Creidy R, Terra R, Bernard D, Khrestchatisky M, Izui S, Chicheportiche Y, Boucraut J. TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 2002;133:116–23.
   PubMed Web of Science ®Google Scholar
• Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999;274:8455–9.
   PubMed Web of Science ®Google Scholar
• Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR: Evidence for a second TWEAK receptor. J Biol Chem 2003;278: 32317–23.
   PubMed Web of Science ®Google Scholar
• Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 2004;64:8968–72.
   PubMed Web of Science ®Google Scholar
• Sanz AB, Justo P, Sanchez-Nino MD, Blanco-Colio LM, Winkles JA, Kreztler M, Jakubowski A, Blanco J, Egido J, Ruiz-Ortega M, Ortiz A. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 2008;19:695–703.
   PubMed Web of Science ®Google Scholar
• Munoz-Garcia B, Martin-Ventura JL, Martinez E, Sanchez S, Hernandez G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: Modulation by atorvastatin. Stroke 2006;37:2044–53.
   PubMed Web of Science ®Google Scholar
• Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány P, Heimbürger O, Marrón B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:110–8.
   PubMed Web of Science ®Google Scholar
• Pongprasobchai S, Jianjaroonwong V, Charatcharoenwitthaya P, Komoltri C, Tanwandee T, Leelakusolvong S, Pausawasdi N, Srikureja W, Chainuvati S, Prachayakul V, Manatsathit S, Kachintorn U. Erythrocyte sedimentation rate and C-reactive protein for the prediction of severity of acute pancreatitis. Pancreas 2010;39:1226–30.
   PubMed Web of Science ®Google Scholar
• Chen CC, Wang SS, Chao Y, Lu CW, Lee SD, Tsai YT, Lo KJ. C-reactive protein and lactate dehydrogenase isoenzymes in the assessment of the prognosis of acute pancreatitis. J Gastroenterol Hepatol 1992;7:363–6.
   PubMed Web of Science ®Google Scholar
• Papachristou GI, Whitcomb DC. Predictors of severity and necrosis in acute pancreatitis. Gastroenterol Clin North Am 2004;33:871–90.
   PubMed Web of Science ®Google Scholar
• Blum T, Maisonneuve P, Lowenfels AB, Lankisch PG. Fatal outcome in acute pancreatitis: its occurrence and early prediction. Pancreatology 2001;1:237–41.
   PubMed Web of Science ®Google Scholar
• Chen ZH, Liu ZH, Yu C, Ji DX, Li LS. Endothelial dysfunction in patients with severe acute pancreatitis: improved by continuous blood purification therapy. Int J Artif Organs 2007;5:393–400.
   Google Scholar
• Przybylowski P, Malyszko JS, Malyszko J. Soluble tumor necrosis factor-like weak inducer of apoptosis plasma levels as a novel biomarker of endothelial function in prevalent orthotopic heart transplant recipients. Transplant Proc 2011;5:1900–3.
   Google Scholar